Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Authors' conclusion
Similar numbers of overall irAEs and severity of Rh-irAEs were observed between older vs younger patients who developed Rh-irAEs after treatment with ICI therapy, suggesting that inflammaging does not play a significant role in Rh-irAEs.
Study context
- Population
- Adults with new rheumatic irAEs (Rh-irAEs) after ICI exposure, CanRIO prospective cohort, 10 Canadian sites, January 2020–March 2023
- Participants
- 139 adults
- Exposure
- Patients aged ≥ 65 years vs < 65 years with Rh-irAEs after ICI
- Youngern = 58reference
- Oldern = 81
- Outcome
- Severity of Rh-irAEs and number of irAEs
Methodological detailsmulticentre (10 Canadian sites)
- Multicentre (10 Canadian sites)
Main finding
As reported in the abstract
- No significant difference in severity of Rh-irAEs (P = 0.84)
- No significant difference in number of immune-related adverse events (irAEs) (P = 0.21)
Observational data: associations, not effects.
Further findings
≥ 3 irAEs · nonsignificant trend
Treatment types for Rh-irAEs and ICI continuation
- Types of treatment for Rh-irAEs similar between groups; ICI continuation did not differ
Incidence of severe Rh-irAEs, ICI-related inflammatory arthritis (subgroup)
- No significant difference (P = 0.51)
Original publication
Effect of Age on Rheumatic Immune-Related Adverse Events: Experience From the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO). J Rheumatol. Published 15 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →